<DOC>
	<DOCNO>NCT02772744</DOCNO>
	<brief_summary>This prospective , cohort study Faculty Medicine , Zagazig University , Egypt . From June December , 2016 , investigator follow patient chronic Hepatitis C virus genotype 4 receive daclatasvir-sofosbuvir treatment regimen within national program Egyptian ministry health population . The primary outcome safety treatment sustain virologic response 12 week discontinuation therapy . For secondary outcome , investigator measure change health relate quality life investigate genetic sequence viral RNA resistant patient .</brief_summary>
	<brief_title>Determining Sustained Virologic Response Declatasvir Egyptian Patients With Hepatitis C Virus Genotype 4</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Patients HCV genotype 4 Age ≥ 18 year HCV RNA≥ 104 IU/mL Screening ECG without clinically significant abnormality . Total serum bilirubin &gt; 3 mg/dl . Serum albumin &lt; 2.8 g/dl . INR ≥ 1.7 Platelet count &lt; 50000/mm3 . Hepatic cell carcinoma except four week intervention aim cure evidence activity dynamic imaging ( CT MRI ) . Extra hepatic malignancy except two year disease free interval Pregnancy inability use contraception . Inadequately control diabetes mellitus ( HbA1c &gt; 9 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis C virus genotype 4</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Virologic Response</keyword>
</DOC>